Dolly A. Vance Net Worth

The estimated Net Worth of Dolly Vance is at least $788 ezer dollars as of 18 December 2014. Ms Vance owns over 1,000 units of Rigel Pharmaceuticals stock worth over $7,458 and over the last 21 years she sold RIGL stock worth over $45,515. In addition, she makes $734,714 as Exec. VP of Corp. Affairs és Gen. Counsel & Corp. Sec. at Rigel Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Vance RIGL stock SEC Form 4 insiders trading

Ms has made over 4 trades of the Rigel Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently she sold 1,000 units of RIGL stock worth $2,220 on 18 December 2014.

The largest trade she's ever made was exercising 15,000 units of Rigel Pharmaceuticals stock on 10 May 2005 worth over $138,000. On average, Ms trades about 572 units every 96 days since 2003. As of 18 December 2014 she still owns at least 575 units of Rigel Pharmaceuticals stock.

You can see the complete history of Ms Vance stock trades at the bottom of the page.

Ms. Dolly A. Vance biography

Dolly A. Vance is the Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. at Rigel Pharmaceuticals.

What is the salary of Ms Vance?

As the Exec. VP of Corp. Affairs és Gen. Counsel & Corp. Sec. of Rigel Pharmaceuticals, the total compensation of Ms Vance at Rigel Pharmaceuticals is $734,714. There are 2 executives at Rigel Pharmaceuticals getting paid more, with David A. Santos having the highest compensation of $1,034,977.

How old is Ms Vance?

Ms Vance is 56, she's been the Exec. VP of Corp. Affairs és Gen. Counsel & Corp. Sec. of Rigel Pharmaceuticals since . There are 4 older and 2 younger executives at Rigel Pharmaceuticals. The oldest executive at Rigel Pharmaceuticals is Raul R. Rodriguez, 60, who is the Pres, CEO & Director.

What's Ms Vance's mailing address?

Dolly's mailing address filed with the SEC is RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Rigel Pharmaceuticals

Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke és Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.

What does Rigel Pharmaceuticals do?

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

Complete history of Ms Vance stock trades at Rigel Pharmaceuticals

Rigel Pharmaceuticals executives and stock owners

Rigel Pharmaceuticals executives and other stock owners filed with the SEC include:

• David A. Santos,
  Exec. VP & Chief Commercial Officer
• Raul R. Rodriguez,
  Pres, CEO & Director
• Dolly A. Vance,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Wolfgang Dummer M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dean L. Schorno CPA,
  Exec. VP & CFO
• Julie Patel,
  Sr. VP of HR
• Tarek Sallam,
  VP of Marketing
• Dr. Esteban S. Masuda,
  Exec. VP of Research
• Joseph Lasaga,
  Sr. VP of Corp. Devel.
• Gary A Lyons,
  
• Brian L. Kotzin,
  
• Jane Wasman,
  
• Kamil Ali Jackson,
  
• Donald G Payan,
  Executive V.P. and CSO
• Peter S Ringrose,
  Director
• Keith Katkin,
  Director
• Ryan D Maynard,
  VP Finance, Acting CFO
• Esteban Masuda,
  Sr. VP Research
• Walter H Moos,
  
• Bradford S Goodwin,
  Director
• Stephen A Sherwin,
  Director
• Eldon C. Iii Mayer,
  EVP & Chief Commercial Officer
• James H Welch,
  VP, CFO and Corp Secretary
• Alan D Frazier,
  Director
• Elliot B Grossbard,
  Sr VP of Med Development
• Anthony Gregg Lapointe,
  
• Nelson Cabatuan,
  VP,Finance & Princ.Acctg. Off.
• Stacy Markel,
  EVP Human Resources
• Joseph Lasaga,
  Sr.VP Bus.Dev.Alliance Mgmt.
• Anne Marie Duliege,
  EVP & Chief Medical Officer
• Partners Ii Incalta Biophar...,
  
• Nicholas J Iii Simon,
  Director
• Bioventures Iii Qp Lpmpm Bi...,
  
• Lukegadicke Ansbert Evnin,
  
• Dennis Henner,
  Director
• Jeanalta Partnersalta Calif...,
  
• Nicholas Galakatos,
  10% owner
• Michael Steinmetz,
  10% owner
• Partners Ii Incalta Biophar...,
  
• Ansbert Gadicke,
  10% owner
• Luke Evnin,
  10% owner
• Bioequities Master Fund Lpm...,
  
• Healthcare Iv Lpfhm Iv Lpfh...,
  
• Lisa Rojkjaer,
  EVP, Chief Medical Officer
• James M Gower,
  CEO and Chairman of the Board
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Hollings Renton,
  Director
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Jean Deleage,
  Director
• Robin D G Cooper,
  Sr. V.P. Pharmaceutical Scs.
• David A Santos,
  EVP, Chief Commercial Officer
• Wolfgang Dummer,
  EVP & CMO
• Alison L. Hannah,
  
• Dean L Schorno,
  EVP & Chief Financial Officer
• Dolly Vance,
  EVP Corp. Affairs, G.C., Sect.
• Raymond J. Furey,
  EVP, GC, CCO & Corp Sec